August 1st 2024
Syngene’s protein production platform uses a cell line and transposon-based technology licensed from Switzerland-based ExcellGene.
March 16th 2024
Mapp Biopharmaceutical will use ProBioGen’s GlymaxX technology for the development of an afucosylated antibody against Marburg virus infection
January 22nd 2024
Abzena has launched its AbZelect platforms, designed for improving cell line development.
November 16th 2023
Lonza’s new GS Effex cell line can help overcome the challenges of developing therapeutic antibodies with increased potency.
October 10th 2022
Cytiva’s acquisition of CEVEC Pharmaceuticals strengthens the company’s cell line development and biomanufacturing capabilities.